Eli Lilly's drive to provide as many treatment options as possible for its weight-loss drug Zepbound has continued ... Companies like Hims & Hers and WeightWatchers have been providing compounded ...

Teladoc stock has declined significantly, from a high of $14 per share in February to $7 per share. Read why I downgrade TDOC ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

Hims & Hers Health (NYSE: HIMS), a telehealth platform ... including Eli Lilly’s in-demand Zepbound. For those seeking upside with lower volatility than individual stocks, take a look at ...

Access our full analysis report here, it’s free. Healthcare Technology for Patients company Hims & Hers Health (NYSE:HIMS) fell 10.2%. Is now the time to buy Hims & Hers Health? Access our full ...

SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the ...

HIMS insiders have traded $HIMS stock on the open market 143 times in the past 6 months. Of those trades, 2 have been purchases and 141 have been sales. Here’s a ...

Below is Validea's guru fundamental report for HIMS & HERS HEALTH INC (HIMS). Of the 22 guru strategies we follow, HIMS rates highest using our Small-Cap Growth Investor model based on the ...

Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, Novo Nordisk ( ...